以阿齐林为基础的功能化支架作为选择性抗血管性活性的内甲蛋白抑制剂
Himalaya Singh1, Nagam Satish2, Tella Ramesh Babu3
1Pharmacology Division, CSIR-Central Drug Research Institute, Lucknow, 226031, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India.
European journal of medicinal chemistry
|June 6, 2024
概括
来自海洋的阿齐林-2-碳氧酸盐通过抑制内甲蛋白-1信号传递,显示出强大的抗血管和抗瘤作用. 这种新型化合物有效地减少瘤生长而不会导致细胞死亡,为癌症治疗提供了一个有希望的新途径.
科学领域:
- 海洋天然产品化学 海洋天然产品化学
- 癌症生物学 癌症生物学
- 血管新生研究研究
背景情况:
- 抗血管生成疗法对于管理瘤负担至关重要.
- 需要新的治疗药物来克服当前治疗方法的局限性.
研究的目的:
- 为了合成和评估新的海基阿齐林化合物对抗血管新生和抗瘤活性.
- 为了研究阿齐林-2-碳氧酸盐的作用机制.
主要方法:
- 合成含有亚齐林的海洋化合物.
- 在体外测试:HUVEC管体生成,细胞活力测试.
- 外体和体内血管新生模型:CAM测定,Matrigel植入,耳朵血管新生.
- 在异种移植小鼠模型中进行体内疗效研究.
- 作用机制研究:DARTS,竞争性结合,基因表达分析.
主要成果:
- 亚齐林-2-碳酸盐抑制了HUVEC管体生成的剂量依赖性,没有细胞毒性.
- 在CAM,Matrigel和耳朵模型中观察到有效的血管生成抑制.
- 抑制内皮细胞迁移而不影响预成型网络.
- 在体内证明了全身暴露和显著的瘤生长抑制.
- 揭示了抑制内甲素-1-介导血管生成的机制.
结论:
- 阿齐林-2-碳酸盐是一种新型的海洋衍生化合物,具有强大的抗血管新生和抗瘤特性.
- 该化合物向内甲蛋白-1信号,提供了一个新的治疗策略.
- 阿齐林-2-碳氧酸盐在抗血管性癌症治疗中显示出临床应用的前景.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
153
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
153
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
617
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
617
Mechanism of Angiogenesis
5.4K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.4K


